Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Niemann N, Jankovic J.

Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x. Review. Erratum in: Drugs. 2018 Mar 10;:. Dosage error in article text.

PMID:
29484607
2.

Valbenazine: First Global Approval.

Kim ES.

Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review.

PMID:
28578484
3.

Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.

Sarva H, Henchcliffe C.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23. Review.

PMID:
29338466
4.

Valbenazine for the treatment of tardive dyskinesia.

Seeberger LC, Hauser RA.

Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2.

PMID:
28699794
5.

VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.

Kim AP, Baker DE, Levien TL.

Consult Pharm. 2018 Apr 1;33(4):201-209. doi: 10.4140/TCP.n.2018.201. Review.

PMID:
29609698
6.

Valbenazine for the treatment of tardive dyskinesia.

Barquero N.

Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review.

PMID:
28276538
7.

Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

Solmi M, Pigato G, Kane JM, Correll CU.

Drug Des Devel Ther. 2018 May 14;12:1215-1238. doi: 10.2147/DDDT.S133205. eCollection 2018. Review.

8.

Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.

Meyer JM.

CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review.

PMID:
28044943
9.

Valbenazine for Tardive Dyskinesia.

Freudenreich O, Remington G.

Clin Schizophr Relat Psychoses. Summer 2017;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Review.

PMID:
28742396
10.

Dopamine depleters in the treatment of hyperkinetic movement disorders.

Jankovic J.

Expert Opin Pharmacother. 2016 Dec;17(18):2461-2470. Review.

PMID:
27819145
11.

Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.

Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.

N Engl J Med. 2017 Jun 29;376(26):2503-2506. doi: 10.1056/NEJMp1704898. Epub 2017 May 10. No abstract available.

PMID:
28489481
12.

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.

Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.

PMID:
28320223
14.

Valbenazine granted breakthrough drug status for treating tardive dyskinesia.

Müller T.

Expert Opin Investig Drugs. 2015 Jun;24(6):737-42. doi: 10.1517/13543784.2015.1029573. Epub 2015 Mar 25.

PMID:
25809133
15.

Deuterium Tetrabenazine for Tardive Dyskinesia.

Cummings MA, Proctor GJ, Stahl SM.

Clin Schizophr Relat Psychoses. 2018 Jan;11(4):214-220. doi: 10.3371/CSRP.CUPR.010318. Review.

PMID:
29341821
16.

Valbenazine for the treatment of tardive dyskinesia.

Müller T.

Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12. Review.

PMID:
28971695
17.

Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.

Paton DM.

Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164. Review.

PMID:
28387387
18.

Valbenazine (Ingrezza) for tardive dyskinesia.

[No authors listed]

Med Lett Drugs Ther. 2017 May 22;59(1521):83-84. No abstract available.

PMID:
28520698
19.

Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.

[No authors listed]

Med Lett Drugs Ther. 2018 Apr 23;60(1545):65-68. No abstract available.

PMID:
29667946

Supplemental Content

Support Center